Neurocrine Expands Rare Disease Portfolio with $2.9B Soleno Buy
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.
Neurocrine will buy Soleno for $2.9B, adding VYKAT XR, the first drug for extreme hunger in rare Prader-Willi syndrome.
Microsoft plans a $10 billion investment in AI and cybersecurity in Japan over 4 years. Sakura Internet stock jumps 20% as it becomes the local AI partner.
AOI got a $71M order for 800G transceivers, doubling recent sales; shipments start Q2 2026 for AI & cloud data centers.
Vericel won a 10-year, $197M BARDA deal to supply NexoBrid, a burn treatment, and expand its use and production in the U.S.
SBA Communications may be sold as big investors show interest; early talks boosted shares, but no deal is certain yet.
GM sales fell 10% in Q1 2026 due to high 2025 sales, storms, and pricey cars; some SUVs did well, EVs dropped 28%.